ACE inhibitors and ARBs are the backbone of MPGN therapy because they lower intraglomerular pressure, reduce proteinuria by 30–40%, and slow eGFR decline [5]. Lisinopril or losartan cost $15–40 monthly as generics. Corticosteroids (prednisone) suppress immune activation and reduce mesangial proliferation; typical dosing is 0.5–1 mg/kg/day (35–80 mg for most adults) tapered by 5–10 mg every 2–4 weeks over 6 months [1]. Side effects include weight gain, mood changes, and increased infection risk, so the goal is the lowest effective dose for the shortest duration.
If proteinuria stays >0.5 g/day after 3–6 months of ACE-I/ARB plus corticosteroids, mycophenolate mofetil (MMF) is added at 1–3 g/day in divided doses [1]. MMF costs $80–200 monthly and works by suppressing B and T cell proliferation. Response takes 8–12 weeks; you'll need monthly CBC and liver function tests to watch for bone marrow suppression or hepatotoxicity. Pegcetacoplan, a newer C3 complement inhibitor, reduced proteinuria by 40% in recent MPGN trials and costs $3,500–5,000 monthly [1].
For severe or refractory MPGN, cyclophosphamide (0.5–1 g/m² IV monthly × 6) plus high-dose corticosteroid pulses (methylprednisolone 500–1000 mg IV × 3) induce remission in 3–6 months [6]. This is reserved for rapidly declining kidney function (eGFR falling >10 mL/min/year) or biopsy-proven crescentic disease. The trade-off is higher infection risk and infertility risk, especially in younger patients. Rituximab (375 mg/m² IV weekly × 4) is an alternative for B cell–driven disease and costs $2,000–3,500 per course [8].
Try This Today
Start a medication diary: write down your ACE-I/ARB dose, prednisone taper schedule, and any side effects (mood, weight, infections). Bring this to each clinic visit so your nephrologist can adjust doses based on your response and tolerability.